Respiratory impairments in patients suffering from Fabry disease – A cross-sectional study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 763 KB, PDF-dokument

Background
The inherited X-linked disorder, Fabry disease, is caused by deficient lysosomal enzyme α-galactosidase A, with progressive accumulation of globotriaosylceramide in multiple organs including the upper and lower airways.
Objectives
To assess pulmonary function at the time of the first pulmonary function test (PFT) performed among the National Danish Fabry cohort and define the prevalence of affected lung function variables.
Materials and Method
A cross-sectional retrospective cohort study of 86 adult patients enrolled in one or both international patient registry databases for Fabry disease, Fabry Registry or FollowME with at least one PFT. The Mainz Severity Score Index (MSSI) was calculated to determine the disease severity. Lung function variables were examined by multivariate regression adjusted for important variables for developing airway illness.
Results
Seventeen patients (20%) showed obstructive airflow limitation and 7 (8%) a restrictive lung deficiency. Smoking status (p = .016) and MSSI (p < .001) were associated with increasing obstructive airway limitation.
Conclusion
The prevalence of affected lung function among the National Danish Fabry cohort was 28%. Patients with classic gene variants frequently developed a decrease in lung function regardless of their smoking status, with significant relationship with disease severity.
OriginalsprogEngelsk
TidsskriftChronic Respiratory Disease
Vol/bind21
Antal sider10
ISSN1479-9723
DOI
StatusUdgivet - 2024

Bibliografisk note

Funding Information:
Ira Hagen Pedersen (specialist nurse) and Casper Kok (laboratory technician) are thanked for excellent assistance. Members from the Danish Fabry Team are thanked for continuously supplying data. Ulla Feldt-Rasmussen’s research salary was sponsored by the Kirsten and Freddy Johansen’s Fund. This investigator-initiated study was sponsored by Sanofi Genzyme.

Publisher Copyright:
© The Author(s) 2024.

ID: 382990594